DRTS — Alpha Tau Medical Cashflow Statement
0.000.00%
Last trade - 00:00- $748.96m
- $682.19m
Annual cashflow statement for Alpha Tau Medical, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 20-F | 20-F | 20-F | 20-F |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Net Income/Starting Line | -27.3 | -33.8 | -29.2 | -31.8 | -42.6 |
| Depreciation | |||||
| Deferred Taxes | |||||
| Non-Cash Items | 14.1 | 9.21 | 7.63 | 9.7 | 12.4 |
| Unusual Items | |||||
| Other Non-Cash Items | |||||
| Changes in Working Capital | 0.585 | -0.307 | 2.49 | 1.17 | 2.19 |
| Change in Prepaid Expenses | |||||
| Change in Accounts Payable | |||||
| Change in Accrued Expenses | |||||
| Change in Payable / Accrued Expenses | |||||
| Net Change in Other Assets & Liabilities | |||||
| Cash from Operating Activities | -11.8 | -23.9 | -18 | -19.8 | -26.7 |
| Capital Expenditures | -2.93 | -0.904 | -6.4 | -2.24 | -6.08 |
| Purchase of Fixed Assets | |||||
| Other Investing Cash Flow Items | 22.2 | -89 | 25.1 | 23 | -14.5 |
| Sale/Maturity of Investment | |||||
| Purchase of Investments | |||||
| Cash from Investing Activities | 19.3 | -89.9 | 18.7 | 20.8 | -20.6 |
| Financing Cash Flow Items | 0 | 93.5 | — | — | — |
| Other Financing Cash Flow | |||||
| Net Issuance / Retirement of Stock | |||||
| Net Issuance / Retirement of Debt | |||||
| Cash from Financing Activities | 0.111 | 96.9 | 5.3 | 0.025 | 45.8 |
| Foreign Exchange Effects | |||||
| Beginning Cash Balance | |||||
| Ending Cash Balance | |||||
| Net Change in Cash | 7.68 | -17.2 | 5.97 | 1.07 | -1.52 |